～ eSOLが中国の有力パートナーと販売契約を締結し、中国の車載ビジネスに本格参入 ～ イーソル株式会社（本社：東京都中野区、代表取締役社長：長谷川勝敏、以下eSOL）は、中国における車載エレクトロニクスソリューションの主力プロバイダーである ...

Sildenafil citrate is the first phosphodiesterase type 5 (PDE-5) inhibitor approved by Food and Drug Administration (1998). PDE-5 inhibition causes an elevation in intracellular cGMP level as cGMP is ...

High tumor mutation burden (TMB) in many cancer types is associated with the production of tumor-specific neoantigens, a favorable outcome and response to immune checkpoint blockade (ICB) therapy.

Group II introns are ribozymes that catalyze a splicing reaction with the same chemical steps as spliceosome-mediated splicing. Many group II introns have lost the capacity to self-splice while ...

SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and ...

Intron provides design services and solutions for Chinese auto electronics and has around 50% market share in the areas that it specializes in. Electronics for new energy vehicles currently contribute ...

Intron Technology’s first-half 2023 result showed very strong revenue growth of 27% driven by strong growth from electric vehicles and automated vehicles. However, several factors, including a large ...

It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- ...

iNtRON Grants Basilea exclusive right for preclinical evaluation with an undisclosed payment Basilea has the option to enter into exclusive License Agreement following the evaluation Basilea has ...

iNtRON Biotechnology (048530) has delivered a -40% change over the past year, with a 52-week range between 2,895 and 5,700. What Is the Average Daily Trading Volume of iNtRON Biotechnology (048530)?